<DOC>
	<DOCNO>NCT01458600</DOCNO>
	<brief_summary>AGO study - adjuvant treatment , NSAID , endocrine ophthalmopathy Graves´ disease Background - Already diagnosis Graves disease approximately 98 % patient morphological change retrobulbar tissue concordant ophthalmopathy . Factors know induce clinical symptom ophthalmopathy mainly unknown . An interesting observation patient stable inactive Graves´ disease develop ophthalmopathy treat glitazone due diabetes type 2 . Glitazones show increase differentiation orbital preadipocytes mature adipocytes . Glitazones PPAR-gamma agonist recently diclofenac show interact PPAR-gamma physiological concentration . Other non-steroidal antiinflammatory drug , NSAID , like indomethacin lack effect . In addition , diclofenac inhibit synthesis prostaglandin also may importance natural ligand PPAR-gamma prostaglandin J. Inflammation adipogenesis hallmarks pathological process Graves ophthalmopathy NSAID like diclofenac may affect . There one early study demonstrate effect NSAID ( indomethacin ) 7 patient effect soft tissue symptom , eye muscle symptom eye protrusion . Aim - investigate diclofenac prevent ophthalmopathy and/or progress ophthalmopathy . Specific aim : 1 . To study frequency clinical ophthalmopathy Graves´ disease 12 month treatment without diclofenac . 2 . To study frequency progress clinical sign symptom ophthalmopathy 12 month treatment without diclofenac . 3 . To study frequency optic neuropathy clinical ophthalmopathy 12 month treatment without diclofenac . Study plan randomisation - 150 patient newly diagnose Graves´disease without ophthalmopathy treat anti-thyroid drug L-thyroxin ( block replace ) accord clinical routine 18 month . These patient randomize diclofenac 50 mg twice daily 12 month .</brief_summary>
	<brief_title>Adjuvant Treatment Graves´ Ophthalmopathy With NSAID ( aGO Study )</brief_title>
	<detailed_description>Adjuvant treatment Graves´ ophthalmopathy NSAID ( aGO study ) 1 . Background . When perform MRI / CT / ultrasound orbital room 98 % patient Graves´ thyrotoxicosis exhibit change ophthalmopathy without clinical symptom endocrine ophthalmopathy ( Burch 1993 ) . Thus , almost patient Graves´ disease risk develop clinical ophthalmopathy . Tobacco exposition treatment radioiodine ar know factor trigger ophthalmopathy factor poorly define . However well know environmental genetic factor importance monozygotic twin show concordance 20 - 50 % . One interesting observation patient inactive stable Graves´ ophthalmopathy develop clinical ophthalmopathy treat pioglitazone due type 2 diabetes ( Starkey 2003 ) . One pathogenic mechanism Graves´ ophthalmopathy increase orbital adipogenesis glitazones know increase volume subcutaneous adipose tissue . Orbital fibroblast patient ophthalmopathy show differentiate adipocytes response rosiglitazone ( Valyasevi 2002 ) . Glitazones PPAR-gamma agonist could interest study effect PPARgamma antagonists endocrine ophthalmopathy . Diclofenac show interact PPAR-gamma physiological concentration antagonise PPAR-gamma mediate effect like adipogenesis preadipocyte cell line 3T3-L1 ( Adamsson 2002 , Vondrichova 2007 ) . In addition diclofenac well-known inhibitor cyclooxygenase effect synthesis prostaglandins example fibroblast , lymphocytes monocyte . The natural ligand PPAR-gamma prostaglandin J ( Forman 1995 ) . To conclude , NSAID like diclofenac may affect synthesis prostaglandin concomittantly antagonise effect natural ligand PPAR-gamma , prostaglandin J2 . We recently demonstrate upregulation immediate early gene , include COX-2 , important function adipogenesis patient severe ophthalmopathy ( Lantz 2005 ) . Previously one study publish treatment ophthalmopathy NSAID , indometacin ( Amemia 1982 ) . Although 7 patient studied effect soft tissue symptom , eye protrusion eye muscle symptom . Due knowledge retrobulbar morphological change patient Graves´ thyrotoxicosis without clinical ophthalmopathy may importance interact early possible . We therefore plan start randomise single-blind study patient receive diclofenac 12 month parallel standard treatment thyrotoxicosis . 2 . Trial design The trial multi-center ( Malmö Stockholm ) , control , single-blind design subject randomise thyrostatics without diclofenac body independent study The total duration study 24 month 12 month treatment without diclofenac addition regular treatment thyrotoxicosis . The follow period 12 month . Decision main treatment thyrotoxicosis base clinical term accord routine Malmö Stockholm give accord protocol TT96 . Patients randomise adjuvant therapy without diclofenac choice main treatment thyrotoxicosis . 2.1 Monitoring The study monitor science nurse formal education monitor clinical trial . 3 . Objectives The primary objective To find diclofenac prevent development ophthalmopathy patient Graves´ disease . The secondary objective : 1 . Determine activity diagnosis ophthalmopathy 2 . Determine time thyrotoxicosis ophthalmopathy 3 . Determine frequency patient corticosteroid require ophthalmopathy 3.1 Endpoints The objective trial examine follow endpoint : Efficacy Primary endpoint : The frequency ophthalmopathy 24 month judge follow clinical sign : . Optic nerve dysfunction 0 . No 1 . Yes Eye-lid edema 0 . No 1 . Yes Chemosis 0 . No 1 . Yes Conjunctival injection 0 . No 1 . Yes Exophthalmos 0 . No 1 . Yes Hertel - base right leave Eye muscle dysfunction 0 . No 1 . Yes Corneal ulcer 0 . No 1 . Yes Summa : Ophthalmopathy present patient one sign . Secondary endpoint : I . Activity ophthalmopathy judged clinical activity score ( CAS ) Spontaneous retrobulbar pain 0 . No 1 . Yes Painful eye-movements 0 . No 1 . Yes Eye-lid erythema 0 . No 1 . Yes Conjunctival injection 0 . No 1 . Yes Chemosis 0 . No 1 . Yes Swollenness caruncula 0 . No 1 . Yes Eye-lid edema swollenness 0 . No 1 . Yes Sum : II . The time thyrotoxicosis ophthalmopathy . III . The frequency corticosteroid require ophthalmopathy . Criteria start steroid treatment : 1 . Risk corneal ulcer without exophthalmos 2 . Double vision within 30 degree 3 . Optic nerve dysfunction . 3.2 Treatment subject All patient fulfill inclusion criterion accept participation study decision main treatment thyrotoxicosis randomise treatment without diclofenac . Patients receive diclofenac 50 mg 1x2 12 month addition standard treatment thyrotoxicosis accord follow routine . Thyrostatics Patients receive p.o . methimazole ( Thacapzol ) 5 mg 3x2 supplement L-thyroxine ( Euthyrox ) 14 day , initially first two week 0.5x1 , thereafter 1x1 . If patient react allergic symptom methimazole , treatment change propylthiouracil ( Tiotil ) 50 mg 3x3 . Adjustment L-thyroxine do help thyroid laboratory parameter ( TSH , fT4 ) titration clinical response . The dose thyrostatics reduce necessary demand dose increase . If necessary , beta-blocker use , primarily propranolol ( Inderal ) 40 mg 1x1-3 metoprolol ( Seloken ) 50 mg 1x1-3 increase depend patient response . 3.3 Measurement laboratory parameter All laboratory analysis perform department Clinical Chemistry , Malmö University Hospital department Clinical Chemistry Karolinska University Hospital . 4 . Rationale treatment Adjuvant treatment already diagnosis thyrotoxicosis choose aim prevent clinical ophthalmopathy due fact morphological change ophthalmopathy orbital room exist Graves´ thyrotoxicosis 98 % patient without clinical symptom . The long period time treatment diclofenac justify knowledge majority patient risk develop ophthalmopathy exhibit clinical symptom within 18 month . 5 . Subjects 5.1 Number patient A total 150 statistically analysable patient ( total number patient include 10 % high compensate loss subject ) , 75 treatment arm include study . 6 . Visits - summary S = Screening test , TSH , fT4 , fT3 , Thyroid Receptor antibody ( TRAK ) , Tissue Peroxidase antibody ( TPO-ak ) , Hb , leukocytes , thrombocyte ( trc ) , diff.-leukocytes , fast B-glucose , HbA1c , Calcium , Albumin , Sodium , Potassium , Creatinine , ASAT , ALAT , ALP , GT , Bil , PK , APTT , U-iodine R = Routine test , TSH , fT4 , fT3 , Hb , Creatinine R+ = Routine test + ASAT , ALAT , ALP , GT , Bil , TRAK , trc , leukocytes , diff . R++ = Routine test + + Fasting B-glucose , U-iodine B = Biobank sample accord GD2002 ( serum , plasma , buffy coat ) C = Clinical control - vital sign , physical examination , weight , eye status O = Ophthalmologist - eye status D = Dietary questionnaire Time -1 week S , B , C , O , D 0 week C 6 week R , C 3 month R+ , B , C 6 month R , B , C 9 month R+ , B , C 12 month R++ , B , C , O , D 15 month R+ , B , C 18 month R , B , C 21 month R , B , C 24 month R++ , B , C , O , D 6.1 Screening Subjects attend first screen visit one week randomisation . Before screen participant provide write information trial . The subject inform , orally write responsibility / right trial well possible advantage / disadvantage trial . Subjects wish participate ask sign date Informed Consent Form prior trial-related activity . Subjects allocate subject number follow perform record : 1 . Assessment inclusion exclusion criterion 2 . Demographic information 3 . Thyroid history 4 . General physical examination 5 . Measurement body weight 6 . Vital sign 7 . Blood sample 8 . Pregnancy test perform per judgement investigator 9 . Concomitant illness medication . 10 . Information choice routine treatment thyrotoxicosis 11 . Actual eye status , perform ophthalmologist within 1 week 12 . An appointment make visit w0 6.2 Randomization visit , w0 Laboratory data information gather screen visit review final decision regard participation trial take . The subject randomise adjuvant treatment without diclofenac . The randomization procedure design independent body . 7 . Trial material The trial perform direct collaboration drug manufacturer . 9 . Statistical consideration The primary evaluation variable proportion present new case endocrine ophthalmopathy . The null-hypothesis difference two treatment alternative accord proportion ( H0 : pi 1 = pi 2 ) . The number patient group perform two-side significance test 5 % level different demand power different value give proportion hypothesis show separate diagram . With 72 patient group 80 % chance ( power ) get significant result real difference 0.2 . The hypothesis test Mantel Haenzels test analysis perform logistic regression take consideration effect prognostic factor .</detailed_description>
	<mesh_term>Graves Disease</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Graves Ophthalmopathy</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<criteria>1 . Graves thyrotoxicosis ( clinical symptom ) 2 . Age 18 75 year 3 . TSH = 0.2 &lt; 0.2 increase fT4 and/or fT3 4 . Signed informed consent 1 . Pregnancy breastfeeding , woman childbearing age use non barrier contraceptives 2 . Previous treatment thyroid disease 3 . Thyrostatics radioiodine treatment 4 . Hypersensitivity NSAID ASA 5 . Congestive heartfailure 6 . Impaired renal function define pcreatinine &gt; 100 mmol/L 7 . ASAT ALAT &gt; 2.5 time upper limit 8 . Alcoholism 9 . Coagulopathy include warfarin treatment 10 . Thrombocytopenia 11 . Previous active gastric ulcera 12 . Inflammatory bowel disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>ophthalmopathy</keyword>
	<keyword>prevention</keyword>
	<keyword>diclofenac</keyword>
</DOC>